We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
- Authors
Chan, Jennifer A; Stuart, Keith; Earle, Craig C; Clark, Jeffrey W; Bhargava, Pankaj; Miksad, Rebecca; Blaszkowsky, Lawrence; Enzinger, Peter C; Meyerhardt, Jeffrey A; Zheng, Hui; Fuchs, Charles S; Kulke, Matthew H
- Abstract
Both tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor and bevacizumab, a monoclonal antibody targeting VEGF, have antitumor activity in neuroendocrine tumors (NETs). Temozolomide, an oral analog of dacarbazine, also has activity against NETs when administered alone or in combination with other agents. We performed a phase II study to evaluate the efficacy of temozolomide in combination with bevacizumab in patients with locally advanced or metastatic NETs.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 24, p2963
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.40.3147